CD33 and leukemia: This may pose a challenge for the determination of an appropriate dosing regimen: target antigen densities vary significantly between individuals [28] and can even vary between the bulk of leukemia cells and the leukemia-initiating stem- or progenitor cells (as is the case for the combined density of CD33 and CD123 on AML LSCs [29], for example).